Zevra Therapeutics, Inc. Notes Payable
Zevra Therapeutics, Inc. (ZVRA) had Notes Payable of $60.09 million as of 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified
us-gaap:NotesPayable · last filed 2025-05-13
- 2025-03-31: Notes Payable $60.09M.
- 2024-12-31: Notes Payable $59.50M.
- 2024-09-30: Notes Payable $58.90M.
- 2024-06-30: Notes Payable $58.33M.
| Period end | Notes Payable |
|---|---|
| 2025-03-31 | $60.09M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $59.50M 10-Q · filed 2025-05-13 |
| 2024-09-30 | $58.90M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $58.33M 10-Q · filed 2024-08-14 |
| 2023-12-31 | $5.07M 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |